Updated tender offer materials provide additional summary information regarding existing Lundbeck offer terms, including existing CVR terms, and additional information regarding existing Alder...
BOTHELL, Wash., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing therapeutic antibodies for the treatment of...
SHAREHOLDER ALERT: WeissLaw LLP Investigates Alder Biopharmaceuticals, Inc. PR Newswire NEW YORK, Sept. 17, 2019 NEW YORK, Sept. 17, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible...
Shareholder Alert: Ademi & O'Reilly, LLP Investigates whether Alder BioPharmaceuticals has obtained a Fair Price in its sale to H. Lundbeck A/S PR Newswire MILWAUKEE, Sept. 16, 2019...
Alder (ALDR) Alert: Johnson Fistel Investigates Proposed Sale of Alder BioPharmaceuticals, Inc.; Are Shareholders Getting a Fair Deal? PR Newswire SAN DIEGO, Sept. 16, 2019 SAN DIEGO, Sept. 16...
- Data analyses from clinical trials to highlight eptinezumab’s efficacy and early, sustained quality of life improvements in the prevention of chronic migraine -- Preclinical data also to be...
Bolt Biotherapeutics Appoints Veteran Executive Randall Schatzman as CEO to Lead the Next Phase of Growth -- Immune-stimulating Antibody Conjugate (ISAC) Immunotherapy Technology Attracts...
BOTHELL, Wash., Aug. 30, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (Nasdaq: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.